Document:

Amendment, dated May 11, 2004, to License Agreement

 Exhibit 10.4 
  
 Boston Life Sciences License Amendment January 2004 HU 1615 
  
 This Amendment to the License Agreement (this “Amendment”) effective the last day signed below of 2004, is entered
into by and between Boston Life Sciences, Inc, a corporation organized and existing under the laws of Massachusetts having its principal offices at 20 Newbury St., 8th Floor, Boston, MA 02116, (hereinafter, “LICENSEE”) and The President
and Fellows of Harvard College, a charitable corporation of Massachusetts, having an office at Office of Technology Licensing and Industry Sponsored Research, Harvard Medical School, Gordon Hall of Medicine, Room 414, 25 Shattuck Street, Boston, MA
02115 (hereinafter “HARVARD”). 
  
 W I T N E S S E T H:

  
 WHEREAS, a License Agreement (the “License
Agreement”) was entered into by and between LICENSEE, HARVARD with an effective date of March 15, 2000; 
  
 WHEREAS, LICENSEE desires to more fully focus its research and development efforts on two diseases; 
  
 WHEREAS, the parties hereto have determined that it is in their
respective best interests to amend Article 1 (“DEFINITIONS”) of the License Agreement to amend the definition of paragraph 1.3, (“FIELD”), and to amend Article VII (“FOREIGN AND DOMESTIC PATENT FILING AND MAINTENANCE”)
and Article VIII (“INFRINGEMENT”) of the License Agreement to more clearly delineate the rights and responsibilities of the parties hereto; 
  
 NOW, THEREFORE, the parties hereto agree as follows: 
  
 1. Amendment to the License Agreement. 
  

	 	(a)	Paragraph 1.3 is hereby amended to read: 

  
 “FIELD shall mean the diagnosis and/or treatment of (i) Attention Deficit Hyperactivity Disorder and (ii) Parkinson’s Disease

  

	 	(b)	Article VII is hereby amended to read: 

  
 PATENT FILING, PROSECUTION AND MAINTENANCE 
  
 7.1 HARVARD shall own (jointly with Organix or other assignees as applicable), file, prosecute and maintain all U.S. and foreign patent applications and
patents included within the PATENT RIGHTS. LICENSEE shall be included in all prosecution-related correspondence with outside patent counsel, shall cooperate with HARVARD in the prosecution, filing and maintenance of the PATENT RIGHTS, and shall be
promptly copied on all documents received from or sent to all patent offices involved in examination, interference proceedings, oppositions and other matters related to the 
  

 Page 1 

 PATENT RIGHTS. HARVARD shall consult LICENSEE on each step of the prosecution process regarding
exclusively licensed PATENT RIGHTS and HARVARD shall incorporate LICENSEE’s comments where reasonably practicable, but final decision making authority shall vest in HARVARD. 
  
 7.2 Upon execution of this Agreement, LICENSEE shall reimburse HARVARD for past and presently payable patent costs for the
preparation, filing, prosecution and maintenance of PATENT RIGHTS. HARVARD shall provide to LICENSEE an itemized invoice of all fees and costs associated with U.S. and foreign patent prosecution, U.S. and foreign patent annuities, and all costs
associated with any patent interference proceedings related to the PATENT RIGHTS (“COSTS”) whether such fees and/or costs were incurred before or after the date of this Agreement. LICENSEE shall have the opportunity to review said
invoices, and shall have the opportunity to discuss questionable billings incurred after the EFFECTIVE DATE either with HARVARD before HARVARD pays the invoiced billings, or directly with HARVARD’s patent counsel, as HARVARD directs. As
directed by HARVARD, LICENSEE shall either pay invoiced billings related to PATENT RIGHTS directly to HARVARD’s patent counsel or shall reimburse to HARVARD the amount of all fees and costs related to PATENT RIGHTS that HARVARD has paid.
LICENSEE shall pay to HARVARD, or to HARVARD’s patent counsel if so directed by HARVARD, all amounts due under each invoice under this paragraph within thirty (30) days of the date of receipt of said invoice. Late payment of these invoices
shall be subject to interest charges of one and one-half percent (1 1/2%) per month. If HARVARD shall license PATENT RIGHTS outside the FIELD to a third party, HARVARD will pay to LICENSEE a sum equal to the pro rata share of past COSTS for PATENT
RIGHTS which are now nonexclusive. HARVARD will also invoice present or future COSTS related to nonexclusive patent rights on a pro rata basis. All pro rata calculations will be made using the number of distinct companies granted a license(s) and no
other bases. 
  
 7.3 HARVARD, Organix and LICENSEE shall
cooperate fully in the preparation, filing, prosecution and maintenance of PATENT RIGHTS exclusive to LICENSEE and of all patents and patent applications exclusively licensed to LICENSEE hereunder, executing all papers and instruments or requiring
members of HARVARD or of Organix to execute such papers and instruments so as to enable HARVARD to apply for, to prosecute and to maintain patent applications and patents in HARVARD’s and other applicable assignees’ names in any country.
HARVARD and LICENSEE shall each provide to the other prompt notice as to all matters which come to its attention and which may affect the preparation, filing, prosecution or maintenance of any such patent applications or patents. After LICENSEE has
shown good and sufficient cause to justify a request that HARVARD choose alternate patent counsel, and after having made reasonable attempts to rectify the situation resulting in said good and sufficient cause, HARVARD will not unreasonably withhold
consent that alternate patent counsel be chosen. In such event, LICENSEE agrees to bear all costs associated with transfer to alternate patent counsel. 
  

 Page 2 

 7.4 LICENSEE may elect to surrender its PATENT RIGHTS in any country upon one-hundred-twenty (120) days
written notice to HARVARD. Such notice shall not relieve LICENSEE from responsibility to reimburse HARVARD for patent-related expenses incurred prior to the expiration of the one-hundred-twenty (120)-day notice period (or such longer period
specified in LICENSEE’s notice). 
  
 7.5 In the event
HARVARD elects not to pursue, maintain or retain a particular PATENT RIGHT licensed to LICENSEE hereunder, HARVARD shall so notify LICENSEE in sufficient time for LICENSEE to assume the filing, prosecution and/or maintenance of such application or
patent at LICENSEE’s expense. In such event, HARVARD shall provide to LICENSEE any authorization necessary to permit LICENSEE to pursue and/or maintain such PATENT RIGHT. LICENSEE shall have no further royalty obligations under this Agreement
with respect to any such PATENT RIGHT. 
  

	 	(c)	Article VIII is hereby amended to read: 

  
 8.7 If a declaratory judgment action is brought naming LICENSEE as a defendant and alleging invalidity of any of the PATENT RIGHTS, HARVARD may elect to
take over the sole defense of the action at its own expense. LICENSEE shall cooperate fully with HARVARD and Organix in connection with any such action. 
  
 2. Definitions. Capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings set forth in the License Agreement.

  
 3. General. Except as expressly set forth above, the License Agreement
as previously amended remains in full force and effect, without change or modification. 
  
 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first set forth above. 
  

					
	For:	 	 	 	 
		
	HARVARD	 	BOSTON LIFE SCIENCES, INC.
			
	 /s/ O. Prem Das

	 	 	 	 /s/ Marc Lanser

	O. Prem Das, Director	 	Name:	 	Marc Lanser MD
	 Office of Technology Licensing and Industry
Sponsored Research
	 	Title:	 	President
	Harvard Medical School	 	 	 	 
			
	5-4-04	 	 	 	 

  

 Page 3Amendment, dated May 18, 2004, to License Agreement

 Exhibit 10.5 
  
 AMENDMENT TO LICENSE AGREEMENT 
 (Agreement number 2639; CMCC 600) 
  
 WHEREAS, CHILDREN’S MEDICAL CENTER CORPORATION (“CMCC”), a corporation organized and existing under the laws of the Commonwealth of Massachusetts and having its principal place of business at 300 Longwood Avenue, Boston, MA
02115, and BOSTON LIFE SCIENCES INC. (“Company”), a corporation organized and existing under the laws of Delaware, and having its principal place of business at 20 Newbury Street, Boston, Massachusetts 02116, entered into a License
Agreement effective as of December 15, 1998 (hereinafter “the Inosine License Agreement”), in which CMCC granted certain license rights to Company under patent rights relating to “Methods for Modulating the Axonal Outgrowth of Central
Nervous System Neurons”, CMCC Case 600, by Dr. Larry Benowitz; and 
  
 WHEREAS, the Inosine License Agreement contemplates the use of Inosine to stimulate the axonal outgrowth of central nervous system neurons; 
  
 WHEREAS, Dr. Larry Benowitz, subsequent to the date of that License Agreement, has discovered methods of stimulating axon regeneration using a combination therapy wherein
agents that inhibit the Nogo Receptor activity are combined with agents that activate the growth pathway of neurons, including Inosine (the “Dual Treatment Method”), CMCC number 1154; 
  
 WHEREAS, CMCC has filed a patent application on the Dual Treatment Method above and is in the
process of licensing such patent rights to Company under a separate agreement (the “Dual Treatment License Agreement”); 
  
 WHEREAS, the Inosine License Agreement includes a provision which allows LICENSEE to deduct from the royalty due to CMCC a certain amount of royalties in the account of
third party patents which could be necessary to produce or sell Licensed Products and Licensed Processes; 
  
 WHEREAS, Children’s and Company have agreed that no royalty reduction provision will apply to the royalties received from the sale of Licensed Product and Licensed Process in the Dual Treatment License Agreement;

  
 WHEREAS, Children’s and Company agree that the existing royalty provision
in the Inosine License Agreement can be used for royalty reduction when intellectual property from third parties is necessary to produce or sell Licensed Product or Licensed Process when License Product or Licensed Process refers to Inosine alone,
but not to Inosine as part of the Dual Treatment Method; 
  
 NOW, THEREFORE, the
parties do hereby agree as follows: 
  
 1. To add the following clause to the end
of Article I (“DEFINITIONS”) in the Inosine License Agreement: 
  

 1 

 K. “Dual Treatment Patent Rights”: Patents and patent applications which claim priority of the
provisional patent application number 60/529,833 filed on 12/16/03, inventor Larry Benowitz, entitled “Method for Axon Regeneration in Mature CNS” 
  
 2. To amend Section (C) of Article IV (“ROYALTIES AND OTHER PAYMENTS”) of the Inosine License Agreement, by adding a sentence at the end of the existing
paragraph, so that the amended paragraph reads: 
  
 C. To the
extent that LICENSEE obtains subsequent to the date of this Agreement licenses to third party patents or other intellectual property that are necessary to produce or sell Licensed Products or Licensed Processes, LICENSEE may deduct from the royalty
due to CMCC fifty percent (50%) of the royalties due on such third party patents or intellectual property up to an amount equal to fifty percent (50%) of royalties hereunder. This provision shall not apply to royalties received from the Net Sale of
Licensed Product or Licensed Processes which involve Dual Treatment Patent Rights. 
  
 3. All other terms and conditions of the License Agreement remain unmodified and in effect. 
  
 4. This Agreement represents the entire understanding of the parties with respect to the subject matter thereof, and supersedes any representations, negotiations, discussions and agreements related thereto, oral or
written. 
  
 5. This Amendment shall take effect on the date of execution by the
last of the parties to sign. 
  

					
	CHILDREN’S MEDICAL CENTER CORPORATION	 	 
		
	         /s/ Donald P. Lombardi

	 	             5/12/04

	By:	 	Donald P. Lombardi	 	Date
	 	 	Chief Intellectual Property Officer	 	 
		
	BOSTON LIFE SCIENCES, INC.	 	 
		
	         /s/ Marc Lanser

	 	             5/18/04

	By:	 	Marc Lanser	 	Date
	 	 	President and COO	 	 

  

 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}]]